ArticleFrontiers in immunology2025
Cadonilimab rechallenge in patients with recurrent or metastatic cervical cancer following prior PD-1/PD-L1 inhibitor failure: a retrospective multicenter study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Patients with recurrent or metastatic cervical cancer (R/M CC) who progress after immunotherapy face limited treatment options. This study aimed to explore whether cadonilimab, a novel bispecific antibody targeting programmed cell death protein 1 (PD-1)/cytotoxic T-lymphocyte antigen-4 (CTLA-4), could effectively treat such patients following PD-1/programmed death-ligand 1 (PD-L1) inhibitor failure. Methods: A retrospective multicenter study was conducted on 29 patients with R/M CC who received cadonilimab treatment after immune checkpoint inhibitor (ICI) failure between August 2022 and April 2024. The study assessed the objective response rate (ORR), the disease control rate (DCR), the progression-free survival (PFS), the overall survival (OS), and the safety profiles. Given the small sample size and its retrospective nature, this study is fundamentally descriptive, and its findings should be interpreted as exploratory. Results: Among the 29 patients, the ORR was 24.1% (7/29) and the DCR was 55.2% (16/29). The median PFS was 5.8 months, while the median OS was 12.1 months. Subgroup analyses identified poorer prognoses for patients with liver metastasis, those with three or more prior treatment lines, and those receiving cadonilimab monotherapy. The most common grade 3 or higher adverse events (AEs) were anemia [8 (27.6%)], decreased white blood cell count [4 (13.8%)], and decreased neutrophil count [4 (13.8%)]. Conclusion: Cadonilimab might offer a promising option with a manageable safety profile for patients with R/M CC who progress after ICI treatment. Further studies with larger sample sizes are needed to confirm these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.